Back to results
US 2016/0102144 A1Published application
Use of Reslizumab To Treat Moderate to Severe Eosinophilic Asthma
AssigneeCephalon, Inc.
InventorsChristopher O'Brien, James Zangrilli, Tushar Shah, Guy Brusselle
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of treating moderate to severe eosinophilic asthma in a patient comprising: 1) identifying a patient having moderate to severe eosinophilic asthma, wherein the patient's symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/μL; and 2) administering to said patient a therapeutically effective dose of reslizumab.
Claims18
A method of treating moderate to severe eosinophilic asthma in a patient comprising:
- identifying a patient having moderate to severe eosinophilic asthma, wherein the patient's symptoms are inadequately controlled with a current asthma therapeutic and wherein the patient's blood eosinophil levels are equal to or greater than 400/μl;
- and
- administering to said patient a therapeutically effective dose of reslizumab.
Dependencies are inferred from the claim text.